XORTX announces results of COVID-19 from Mount Sinai

CALGARY, Alberta, October 14, 2021 (GLOBE NEWSWIRE) – XORTX Therapeutics Inc. (“XORTX“or the”Society“) (CSE: XRX | NASDAQ: XRTX), a therapeutic pharmaceutical company focused on developing innovative therapies to treat progressive renal failure, is pleased to announce and share the results of a summary of the American Society of Nephrology Kidney Week Written by Dr. Steven Coca and Team at Mount Sinai Hospital Network and Icahn School of Medicine, to be published online Friday, October 15, 2021. This study was sponsored by XORTX Therapeutics Inc. and the reported results support the provisional patent and the XORTX applications announced in March 2020 and March 2021.

This clinical study of patients hospitalized due to COVID-19 between March 1, 2020 and December 31, 2020 characterized the association between elevated serum uric acid levels and major renal adverse events (MAKE), as well as a heart injury. Since its emergence, COVID-19 has been reported to be associated in some people with acute damage to the kidney, cardiovascular, neurological and other systems.1 The abstract submitted online for the upcoming American Society of Nephrology presents data supporting the conclusions that “In patients admitted to hospital with COVID-19, higher uric acid levels were independently associated with MAKE and mortality in a dose-dependent manner. In addition, hyperuricaemia was associated with higher levels of procalcitonin and troponin.

The concentrations of procalcitonin and troponin are often used as markers for the interpretation of the severity of sepsis and heart damage, respectively. 2.3

Dr Steven Coca commented, “There are many factors likely to contribute to acute kidney disease (AKI) in patients hospitalized for COVID. The results of our study underline the importance of prescribing a serum uric acid level in hospitalized patients on admission or at the latest at the start of clinical ARI, since hyperuricemia may be a modifiable risk factor ( i.e. treatable) exacerbation of kidney injury. . “

Dr Allen Davidoff said: “XORTX is pleased to be able to draw attention to this important work and acceptance of this peer-reviewed abstract as well as its presentation at the American Society of Nephrology Kidney meeting. Week. Data from this clinical study support our claim that hyperuricemia may be a key factor in acute kidney injury and now multiorgan injury in people hospitalized with COVID-19 infection. “

Definition: The MAKE criteria are defined as: MAKE (major renal adverse events) is a composite of persistent decline in renal function (> 25% drop in eGFR), new hemodialysis requirement and death. MAKE was evaluated 30, 60 or 90 days after the diagnosis of AKI.

About COVID-19 and Acute Kidney Injury

Acute renal failure (AKI) has been identified as an independent risk factor for in-hospital patient mortality from COVID-195. Recent data from the United States indicates that 25 to 35% of patients hospitalized with COVID-19 develop an ARI.6-8 Up to 20% of them need kidney replacement therapy (RRT), and the death rate in patients with AKI as part of COVID-19 is several times higher than in patients without IRA.7 Additionally, proteinuria (69-85%) and hematuria (50-65%) are common in COVID-19.6-8 In previous peer-reviewed studies, viral infections such as influenza, when severe, can produce increased lung cell debris, endothelial cell debris, and serum uric acid (SUA) levels in the circulation. as well as increased expression of cytokines. Coronavirus infection appears to follow this pattern.

XORTX develops XRx-101a therapy designed to decrease high serum uric acid levels and inhibit purine metabolism by xanthine oxidase for the treatment and prevention of ARI in people with acute kidney disease.

The references:

  1. Gupta A_Extrapulmonary manifestations of COVID-19_Natural medicine_preprint_July10_2020s41591-020-0968-3
  2. Taylor R., Jones A., Kelly S., Simpson M., Mabey J., A Review of the Value of Procalcitonin as a Marker of Infection, Cureous 9 (4): e1148, 2017
  3. Babuin L., Jaffe AS, Troponin: the biomarker of choice for the detection of cardiac lesions, CMAJ, 174 (3): 353, 2006
  4. Billings FT, Shaw AD, Endpoints for Clinical Trials in Acute Kidney Injury, Nephron Clin Practice, 127
    (0): 89-93, 2014 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480222/#:~:text=MAKE%20(major%20adverse%20kidney%20events,90%20days % 20after% 20AKI% 20diagnosis.
  5. Source: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
  6. Hirsch JS, Ng JH, Ross DW et al. Acute kidney injury in hospitalized patients with Covid-19. Kidney Int. 2020.
  7. Chan L, Chaudhary K, Saha A, et al. Acute kidney injury in hospitalized patients with COVID-19. medRxiv. 2020: 2020.2005.2004.20090944.
  8. Mohamed MM, Lukitsch I, Torres-Ortiz AE, et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney360. 2020: 10.34067 / KID.0002652020.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for coronavirus / COVID-19 infection and XRx-225 is a program preclinical stage for type 2 diabetic nephropathy (T2DN). XORTX is working to advance its products into clinical development that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit uric acid production. At XORTX Therapeutics, we are committed to developing drugs to improve the quality of life and future health of patients. Additional information about XORTX Therapeutics is available at www.xortx.com.

For more information, please contact:
Allen Davidoff, CEO Nick Rigopulos, Director of Communications
[email protected] or +1 403 455 7727 [email protected] or +1 617 901 0785
Dr. David Sans, Head of Business Development in New York
[email protected] or +1 347 573 0541

The CSE and the Nasdaq have neither approved nor disapproved the contents of this press release. No stock exchange, securities commission or other regulatory authority has approved or disapproved of the information contained in this document.

This press release includes forward-looking statements that are subject to assumptions, risks and uncertainties. Statements in this press release that are not purely historical are forward-looking statements, including, without limitation, any statement regarding the intentions, plans, estimates, beliefs or expectations of the Company. Although the Company believes that these intentions, plans, estimates, beliefs and expectations in this press release are reasonable, there can be no assurance that such intentions, plans, beliefs and expectations will prove to be correct. The Company cautions readers that all forward-looking statements, including, without limitation, those relating to the future operations and business prospects of the Company, are based on assumptions, none of which can be assured, and are subject to certain risks and uncertainties that could lead to actual events or results. differ materially from those indicated in forward-looking statements. Readers are cautioned to rely on their own assessment of these risks and uncertainties and not to place undue reliance on forward-looking statements. All forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements, or to update the reasons why actual events or results might differ or differ. those projected in forward-looking statements. . The Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

Future of American agriculture demands high-speed internet solutions

ST. LOUIS – A new report, funded by the United Soybean Board and produced by …

Leave a Reply

Your email address will not be published. Required fields are marked *